Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
KYTX
STRONG SELLKyverna Therapeutics, Inc. · Healthcare · United States · $450M · Avg Vol: $9M/d
COMPANY DESCRIPTION
Kyverna Therapeutics, Inc. is a clinical-stage biotechnology company developing cell therapies for serious autoimmune diseases. The company's lead candidate, KYV-101, is an autologous CD19-targeting CAR T-cell therapy in development for B-cell driven autoimmune conditions. Kyverna's innovative approach aims to address significant unmet needs in chronic autoimmune disorders, leveraging advanced cell therapy technology.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.7M | 7.0M | 0 | 0 | 0 | 24.2% | — | — | 17.6M | 20.2% |
| EPS | -1.02 | -1.12 | -1.48 | -3.33 | -3.64 | — | -3.17 | -2.88 | -2.95 | — |
| Shares | 40.8M | 40.8M | 43.1M | 43.2M | 60.4M | +47.9% | 60.8M | — | — | — |
| Debt | 5.6M | 10.6M | 9.1M | 8.2M | 29.0M | 51.2% | 33.8M | — | — | — |
| Equity | -46.3M | -74.0M | -131.4M | 266.6M | 232.3M | -12.9% | — | — | — | — |
| Op CF | -22.2M | -36.1M | -52.4M | -114.3M | -153.7M | — | -150.4M | — | — | — |
| Inv CF | -1.3M | -14.1M | -8.8M | -160.9M | 40.0M | — | — | — | — | — |
| Fin CF | 72.5M | 11.9M | 58.1M | 337.1M | 141.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of KYTX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| KYTX | Kyverna Therapeutics, Inc.(you) | $450M | 10 | STRONG SELL |
| PROK | ProKidney Corp. | $453M | 7 | STRONG SELL |
| VSTM | Verastem, Inc. | $532M | 10 | STRONG SELL |
| EIKN | Eikon Therapeutics, Inc. | $482M | 12 | STRONG SELL |
| EVMN | Evommune, Inc. | $409M | 8 | STRONG SELL |
| EDIT | Editas Medicine, Inc. | $399M | 7 | STRONG SELL |
| ALT | Altimmune, Inc. | $539M | 12 | STRONG SELL |
| CABA | Cabaletta Bio, Inc. | $439M | 15 | STRONG SELL |
| CMPX | Compass Therapeutics, Inc. | $373M | 7 | STRONG SELL |
| DNA | Ginkgo Bioworks Holdings, Inc. | $481M | 15 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.7%